Clinical Trial Update: Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating ferric carboxymaltose for iron deficiency anemia in patients with gastrointestinal stromal tumor undergoing systemic therapy; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue, Gastrointestinal Stromal Tumor With Neurogenic Differentiation | Phase 2 | Status: TERMINATED | Results posted: 2020-04-06